Few misconceptions in hormone medicine have done more harm than the belief that testosterone is bad for cardiovascular health. This idea — largely based on theoretical concerns and early, flawed case reports — has led millions of men with low testosterone to remain untreated, suffering cardiovascular risk factors that testosterone deficiency itself creates.
The evidence base has shifted substantially. Multiple large observational studies and the landmark TRAVERSE trial (published in 2023) have provided the most comprehensive cardiovascular safety data on testosterone therapy to date. The TRAVERSE trial specifically found no increased risk of major adverse cardiovascular events (MACE) in men with hypogonadism treated with testosterone gel compared to placebo — a finding that directly contradicts the fear-based narrative that has dominated clinical decision-making for decades.
Furthermore, testosterone deficiency itself is a cardiovascular risk factor. Low testosterone is independently associated with increased visceral adiposity, insulin resistance, dyslipidemia, hypertension, inflammation (elevated CRP, IL-6), endothelial dysfunction, and mortality from cardiovascular disease. The metabolic syndrome — a cluster of cardiovascular risk factors — is significantly more prevalent in hypogonadal men. Correcting testosterone deficiency addresses multiple cardiovascular risk pathways simultaneously.
Monitoring during testosterone therapy should include hematocrit (testosterone stimulates red blood cell production — excessive elevation increases blood viscosity and clotting risk), blood pressure, lipid panel, and estradiol (since elevated estrogen, often from excess testosterone aromatization, is a cardiovascular risk factor in men). With appropriate monitoring and dosing, TRT is a cardiovascular-protective intervention for men with documented hypogonadism, not a risk.
Get the full picture on your cardiovascular and hormonal health. Call 844-734-2112 or contact our team today.